Sang Bin Hong1, Tae Young Lee2, Yoo Bin Kwak3, Sung Nyun Kim1, Jun Soo Kwon4. 1. Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea. 2. Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea; Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: leetaey@snu.ac.kr. 3. Department of Brain & Cognitive Sciences, Seoul National University College of National Sciences, Seoul, Republic of Korea. 4. Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea; Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Brain & Cognitive Sciences, Seoul National University College of National Sciences, Seoul, Republic of Korea.
Abstract
OBJECTIVES: Illness course in individuals at clinical high risk (CHR) status for psychosis is heterogeneous, which limits effective treatment for all CHR subgroups. Baseline predictors of positive symptom trajectory in the CHR group will reduce such limitations. We singled out the putamen, thought to be involved in the generation of the key schizophrenia symptoms early in the course of disease, as a potential predictor of positive symptom trajectory in CHR patients. METHOD: We recruited 45 CHR patients and 29 age- and gender-matched healthy controls (HC). The CHR group was divided into patients with positive symptom reduction (CHR-R) and patients without positive symptom reduction (CHR-NR) at 6 months. Comparisons were made between the baseline putamen volumes of CHR-R, CHR-NR and HC groups. The relationship between baseline putamen volumes and clinical measures was investigated. RESULTS: Left putamen volumes of CHR-R patients were significantly smaller than those of HCs (p=0.002) and of CHR-NR patients (p=0.024). CHR-R patients had significantly reduced leftward laterality compared to HCs (p=0.007). In the CHR-R group, bilateral putamen volumes were correlated with positive symptom severity at baseline (r=-0.552, p=0.001) and at 6 months (r=-0.360, p=0.043), and predicted positive symptom score change in 6 months at a trend level (p=0.092). CONCLUSION: Smaller left putamen volumes in CHR-R patients, and the correlation between positive symptom severity and putamen volumes suggest that putamen volume is a possible risk-stratifier and predictor of clinical course in the CHR population.
OBJECTIVES: Illness course in individuals at clinical high risk (CHR) status for psychosis is heterogeneous, which limits effective treatment for all CHR subgroups. Baseline predictors of positive symptom trajectory in the CHR group will reduce such limitations. We singled out the putamen, thought to be involved in the generation of the key schizophrenia symptoms early in the course of disease, as a potential predictor of positive symptom trajectory in CHR patients. METHOD: We recruited 45 CHR patients and 29 age- and gender-matched healthy controls (HC). The CHR group was divided into patients with positive symptom reduction (CHR-R) and patients without positive symptom reduction (CHR-NR) at 6 months. Comparisons were made between the baseline putamen volumes of CHR-R, CHR-NR and HC groups. The relationship between baseline putamen volumes and clinical measures was investigated. RESULTS: Left putamen volumes of CHR-R patients were significantly smaller than those of HCs (p=0.002) and of CHR-NR patients (p=0.024). CHR-R patients had significantly reduced leftward laterality compared to HCs (p=0.007). In the CHR-R group, bilateral putamen volumes were correlated with positive symptom severity at baseline (r=-0.552, p=0.001) and at 6 months (r=-0.360, p=0.043), and predicted positive symptom score change in 6 months at a trend level (p=0.092). CONCLUSION: Smaller left putamen volumes in CHR-R patients, and the correlation between positive symptom severity and putamen volumes suggest that putamen volume is a possible risk-stratifier and predictor of clinical course in the CHR population.
Authors: Du Lei; Kun Qin; Walter H L Pinaya; Jonathan Young; Therese Van Amelsvoort; Machteld Marcelis; Gary Donohoe; David O Mothersill; Aiden Corvin; Sandra Vieira; Su Lui; Cristina Scarpazza; Celso Arango; Ed Bullmore; Qiyong Gong; Philip McGuire; Andrea Mechelli Journal: Schizophr Bull Date: 2022-06-21 Impact factor: 7.348
Authors: Qiang Luo; Qiang Chen; Wenjia Wang; Sylvane Desrivières; Erin Burke Quinlan; Tianye Jia; Christine Macare; Gabriel H Robert; Jing Cui; Mickaël Guedj; Lena Palaniyappan; Ferath Kherif; Tobias Banaschewski; Arun L W Bokde; Christian Büchel; Herta Flor; Vincent Frouin; Hugh Garavan; Penny Gowland; Andreas Heinz; Bernd Ittermann; Jean-Luc Martinot; Eric Artiges; Marie-Laure Paillère-Martinot; Frauke Nees; Dimitri Papadopoulos Orfanos; Luise Poustka; Juliane H Fröhner; Michael N Smolka; Henrik Walter; Robert Whelan; Joseph H Callicott; Venkata S Mattay; Zdenka Pausova; Jean-François Dartigues; Christophe Tzourio; Fabrice Crivello; Karen F Berman; Fei Li; Tomáš Paus; Daniel R Weinberger; Robin M Murray; Gunter Schumann; Jianfeng Feng Journal: JAMA Psychiatry Date: 2019-04-01 Impact factor: 21.596